Upadacitinib
14 Inquiries
1310726-60-3
Pharmaceutical Grade
99%
As per Customer's requirement
2024-12-08
API,Intermediate
-
Product Description
-
Seller Information
-
Inquiry History
-
DescriptionECHEMI Editorial ReferenceUpadacitinib is a JAK1 inhibitor (IC50= 47 nM). It is selective for JAK1 over JAK3 and tyrosine kinase 2 (Tyk2; IC50s = 2,304 and 4,690 nM, respectively), as well as a panel of 83 additional kinases at 1 μM, but does inhibit JAK2, Rho-associated kinase I (ROCK1), and ROCK2 (IC50s = 120, 920, and 430 nM, respectively). Upadacitinib decreases cytokine-induced STAT phosphorylation in a variety of human cells with IC50values ranging from 1.6 to 649 nM. It reducesM. tuberculosis-induced paw swelling and bone erosion in a rat model of arthritis when administered at doses of 1, 3, and 10 mg/kg twice per day for 17 days. Formulations containing upadacitinib have been used in the treatment of rheumatoid arthritis.
Upadacitinib was discovered by AbbVie scientists, RINVOQ is a JAK inhibitor that is being studied in several immune-mediated inflammatory diseases. In human leukocyte cellular assays, RINVOQ inhibited cytokine-induced STAT phosphorylation mediated by JAK1 and JAK1/JAK3 more potently than JAK2/JAK2 mediated STAT phosphorylation. Upadacitinib (RINVOQ) received FDA approval in 2019 for the treatment of moderate to severe RA.Basic Info-
Product Name:
Upadacitinib
Other Name:Upadacitinib;Upadacitinib (ABT-494);ABT-494 (Upadacitinib);Upadacitinib (Rinvoq);ABT-494; ABT494; ABT 494;CS-2730;(3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, Upadacitinib;1-Pyrrolidinecarboxamide, 3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)-, (3S,4R)-
CAS No.:1310726-60-3
Molecular Formula:C17H19F3N6O
InChIKeys:WYQFJHHDOKWSHR-MNOVXSKESA-N
Molecular Weight:380.37
Exact Mass:380.37
EC Number:213-161-9
Color/Form:White to off-white
Categories:
Characteristics-
PSA:
78.32
XLogP3:3.2367
Density:1.56±0.1 g/cm3(Predicted)
PKA:11.89±0.60(Predicted)
Critical Temperature & Pressure:Store at -20°C
Hazard IdentificationClassification of the substance or mixture
no data available
GHS label elements, including precautionary statements
Pictogram(s) no data available Signal word no data available
Hazard statement(s) no data available
Precautionary statement(s) Prevention no data available
Response no data available
Storage no data available
Disposal no data available
Other hazards which do not result in classification
no data available
Handling and StoragePrecautions for safe handling
Handling in a well ventilated place. Wear suitable protective clothing. Avoid contact with skin and eyes. Avoid formation of dust and aerosols. Use non-sparking tools. Prevent fire caused by electrostatic discharge steam.
Conditions for safe storage, including any incompatibilities
Store the container tightly closed in a dry, cool and well-ventilated place. Store apart from foodstuff containers or incompatible materials.
-
-
Seller Information
-
Business Type:
Distributor
-
Main Products:
API,Intermediate
-
Payment Terms:
TT against copy of documents,L/C
-
Average lead Time:
30
-
Total Annual Revenue:
Above $100 million
-
Total Employees:
201-300
About Echemi Pharmaceutical
Echemi’s philosophy is to seek for higher quality, to explore frontier area. The progress of human society, the extension of life expectancy, and the conquest of disease are all derived from the numerous businesses and individuals who have quietly dedicated themselves in the pharmaceutical industry. It’s the controlling of supply chain quality that ensures the efficacy. It’s the continuous exploration that promotes the development of the pharmaceutical industry and benefits more future generations. The pursuit of high quality requires all partners of Echemi Pharmaceutical to be screened, whether its certificate, qualification or scale. In the field of renewal, we will embrace all new changes and make more contributions to the development of pharmaceutical industry.
Advantage for Pharmaceutical
• Having been working in pharmaceutical field for more then 15 years, we have experienced regulatory team, quality control team, sourcing team, technical support team, and logistics team. And we are familiar with the regulatory requirements from different areas, can offer tailored service for our customers.
• We have hundreds of strategic partners for APIs, intermediates, and custom synthesis. All of our partners are ready to support our customers with documents, and be audited.
• We can offer custom synthesis for some new chemical structures and some materials which there are no reliable suppliers.
Product Category
We care for human and animal health and we are committed to creating a better social environment.
• Human API
• Intermediate
• Veterinary API
• Agrochemical
• Fine Chemical
• Custom Synthesis
-
-
Inquiry History14 Inquiries
Country Product Purchase Quantity Date Posted 
India
Upadacitinib
30.00 KG May 20, 2024
India
Upadacitinib - ABT- 494
5.00 KG Jan 19, 2024
India
Upadacitinib
5 KG Jan 17, 2024
India
Upadacitinib
10.00 KG Mar 6, 2024 
Hongkong, China
Upadacitinib
50 MG Apr 7, 2026
India
Upadacitinib
100 G Nov 24, 2025
India
Upadacitinib
5 KG Nov 29, 2023 
Pakistan
UPADACITINIB
7 KG Oct 8, 2023
Pakistan
Upadacitinib
1 KG Feb 17, 2025
Pakistan
UPADACITINIB
0.51 KG Feb 25, 2026
India
Upadacitinib
1000.00 KG Feb 13, 2025
India
URSODEOXYCHOLIC ACID
10.00 KG Mar 6, 2024
India
Acarbose
10.00 KG Mar 6, 2024
India
Ripretinib
10.00 KG Mar 6, 2024 Post an enquiry for this product